Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary

Published on 3 Sep 2024 on Pharmaceutical Technology · via Yahoo Finance

Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant in a potential $1.2bn...

Read the rest of the article

Start tracking your investments with Statfolio

Organon (OGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a g...

Zacks · via Yahoo Finance 15 Nov 2024

A pharmaceutical ingredient that’s been a key component in nasal decongestants for decades is hav...

MedCity News 8 Nov 2024

If it’s like the Sahara in there, penetration may even cause micro-tears that you don’t notice un...

Self · via Yahoo News 4 Nov 2024

Investors in Organon & Co. (OGN Quick QuoteOGN - Free Report) need to pay close attention to the...

Zacks 25 Oct 2024

There's a significant incentive for building up a strong portfolio of high-yielding dividend stoc...

The Motley Fool 24 Oct 2024

Quest Diagnostics completed its acquisition of select assets from OhioHealth’s laboratory service...

NJBIZ 23 Oct 2024

The most oversold stocks in the health care sector presents an opportunity to buy into undervalue...

Benzinga 22 Oct 2024

Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant in a potential $1.2bn...

Pharmaceutical Technology · via Yahoo Finance 3 Sep 2024

Shares of Tenet Healthcare Corporation THC have surged 88.7% in the past year compared with the i...

Zacks via Yahoo Finance 30 May 2024

Organon (OGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a g...

Zacks via Yahoo Finance 30 May 2024